
Wegovy Weight Loss Drug Faces Legal Challenges, Expanded Options, and Promising Clinical Trials in 2025
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
Explore the rapidly evolving landscape of Novo Nordisk's groundbreaking weight loss medication in this comprehensive episode. Host Alexandra Reeves breaks down the latest Wegovy developments, including FDA applications for a new oral formulation, expanding legal challenges related to side effects, and significant price reductions making the treatment more accessible to patients.
Discover eye-opening clinical trial results showing enhanced effectiveness with higher dosages, where patients lost nearly 19% of their body weight, and learn how Wegovy's tremendous market success ($9.4 billion in sales) is reshaping pharmaceutical priorities. The episode also examines resolved supply issues, intensifying competition from Eli Lilly's Zepbound, and the broader societal implications of these GLP-1 medications beyond obesity treatment.
Whether you're a current user, healthcare professional, or simply interested in the intersection of medical innovation and healthcare economics, this episode offers essential insights into one of today's most transformative medications and the controversies surrounding its use.
activate_mytile_page_redirect_t1
What listeners say about Wegovy Weight Loss Drug Faces Legal Challenges, Expanded Options, and Promising Clinical Trials in 2025
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.